Kevin Kimberlin

Kevin Kimberlin is chairman of Spencer Trask & Co., a technology firm.

Technology

In 1982, Kimberlin invested in Millicom, a startup selected by the Federal Communications Commission to demonstrate the feasibility of cellular telephony.[1][2][3] As advisor to the CEO, he structured the first equity financing for Millicom, which led the Racal–Millicom joint venture —subsequently renamed Vodafone Group plc.[4]

Kimberlin co-founded Ciena Corporation with Optelecom and David R. Huber to commercialize the first dense wave division multiplexing (DWDM) system.[5][6][7] This system is the common basis of all high-capacity fiber communications networks.[8]

Prior to its public offering, Kimberlin was the sole general partner of Next Level Communications, a broadband access company, 20% owned by Kimberlin LLC and 80% owned by General Instrument Corporation.[9] Kimberlin took Next Level through its IPO, achieving a market capitalization of $17 billion before it was acquired by Motorola in 2002.[10]

Medicine

In 1986, Kimberlin co-founded the Immune Response Corporation with Jonas Salk.[11] The Immune Response Corporation patented the basis of the first FDA approved cancer vaccine, and contributed to developments in the field of immunotherapy.[12]

He then co-founded Myriad Genetics, the first human genome company, with Walter Gilbert, Peter Meldrum, and Mark Skolnick, the scientist who, with several colleagues, devised the gene-mapping technique that preceded the Human Genome Project.[13] Myriad Genetics discovered the breast cancer gene, BRCA1, in 1994.[14]

Osiris Therapeutics, also co-founded by Kevin Kimberlin, patented and developed the mesenchymal stem (stromal) cell (MSC). As of June 2020, a search of MSC in ClinicalTrials.gov turned up 1,116 clinical trials registered to treat 928 different medical conditions. Using the MSC as a drug, Osiris received the world's first regulatory approval for a stem cell-based therapy.[15]

Kimberlin helped launch Health Dialog based on the research of John Wennberg. Health Dialog provided $130 million in support of Wennberg's evidence-based medicine efforts.

Kimberlin was a founding shareholder in Robert Langer's first company, Enzytech which later merged to form Alkermes.[16]

Philanthropy

Kimberlin's philanthropic activities in environmental science, education, and creativity include the Audubon Society, Harvard University and Yaddo, where Kimberlin is a lifetime honorary director.[17]

Personal life

In 2014, Kimberlin was reported as one of a number of "prominent investors [who] have taken to Transcendental Meditation".[18] He received his Bachelor of Sciences degree from Indiana University and his master's degree from Harvard University.

References

  1. ↑ Garrard, Garry (1997). Cellular Communications: Worldwide Market Development. Artech House Publishers. p. 32.
  2. ↑ Forrester, Tom (1985). The Information Technology Revolution. The MIT Press. p. 142.
  3. ↑ Mack, Eric. "There are now more gadgets on Earth than people". CNET. Retrieved 2023-02-02.
  4. ↑ Merriden, Trevor (2003). Rollercoaster: The Turbulent Life and Times of Vodafone and Chris Gent. Capstone Publishing Ltd. (A John Wiley & Sons Co.). p. 21.
  5. ↑ Anders, George. "With Ciena, Investors Hit a Jackpot That's One for the Record Books". WSJ. Retrieved 2023-02-02.
  6. ↑ Hecht, Jeff (October 2016). "Boom, Bubble, Bust: The Fiber Optic Mania". Optics and Photonics News: Cover story.
  7. ↑ "Fiber-Optic Technology Draws Record Stock Value". The New York Times. 3 March 1997.
  8. ↑ Grobe, Klaus and Eiselt, Michael; Wavelength Division Multiplexing: A Practical Engineering Guide, John T Wiley & Sons; October 2013. p. 2.
  9. ↑ "Motorola deal spurred by changes in tech - Philadelphia Business Journal".
  10. ↑ "Next Level Partners LLC Tenders Shares to Motorola".
  11. ↑ Jacobs, Charlotte (2015-01-01). Jonas Salk: A Life. Oxford University Press. pp. 432. ISBN 9780199334414. immune response corporation kimberlin.
  12. ↑ "Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine". Drugs in R&D. 7 (3): 197–201. 2006. doi:10.2165/00126839-200607030-00006. PMID 16752945.
  13. ↑ Davies, Kevin and White, Michael. "Breakthrough: The Race to find the Breast Cancer Gene". Wiley Publishing. page 199
  14. ↑ Waldholz, Michael. "Scientists Say They’ve Found Gene That Causes Breast Cancer—Study Could Lead to Test For Those at High Risk Of Inheriting Disease." Wall Street Journal [New York] 14 Sept. 1994: B7
  15. ↑ Pollack, Andrew. "A Stem-Cell-Based Drug Gets Approval in Canada". The New York Times. May 17 2012.
  16. ↑ Langer, Robert; Zhang, Shuguang (2015-11-19). "The Struggles and Dreams of Robert Langer". Series in Structural Biology. 5. doi:10.1142/9918. ISBN 978-981-4749-03-9. ISSN 2424-8398.{{cite journal}}: CS1 maint: periodical has ISBN (link)
  17. ↑ Gelder, Lawrence. "Footlights: Looking Ahead". The New York Times. December 24 1998.
  18. ↑ Goodkind, Nicole. "Could this be the key to success on Wall Street? Hedge fund billionaire Ray Dalio thinks so". Retrieved 15 May 2014. The technique ... is popular with folks like Bridgewater's Ray Dalio (who offers TM to his 400 employees), Bill Gross, Dan Loeb, Nigol Koulajian (Quest Partners) and Kevin Kimberlin (Spencer Trask & Co).
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.